Ibogaine Research & Clinical Trials 2025: The Complete Update

2025 is shaping up to be the most consequential year in ibogaine research history. With a landmark Stanford study already published in Nature Medicine, an active VA-sponsored clinical trial underway, new Canadian research programs, and growing federal interest following a presidential executive order, ibogaine is moving rapidly from fringe treatment to mainstream medicine. Here is everything happening right now.

The Stanford/VA Study That Changed Everything

In January 2024, Stanford University published results of a study in Nature Medicine that sent shockwaves through both the addiction medicine and veteran health communities. Researchers led by Dr. Nolan Williams studied 30 U.S. special operations veterans who received ibogaine treatment at a clinic in Mexico.

The results were extraordinary:

• 88% reduction in PTSD symptom severity at 1-month follow-up
• 87% reduction in depression symptoms
• 81% reduction in anxiety symptoms
• Significant improvements in cognitive function for veterans with traumatic brain injury
• Reductions in alcohol and drug use across the group

These were not modest improvements. These were life-altering changes in people who had exhausted conventional treatment options. The study was rigorous enough — and the results dramatic enough — that it immediately drew federal attention.

The Presidential Executive Order (2024)

In late 2024, President Trump signed an executive order directing federal agencies to accelerate research into ibogaine as a treatment for veterans with PTSD and TBI. The order directed the VA and Department of Defense to fund clinical trials and explore regulatory pathways, citing the “extraordinary potential” of the treatment for service members.

This was a historic moment: the first time a sitting president had explicitly directed federal resources toward psychedelic medicine research for veterans. It accelerated what was already a rapidly moving field.

Active Clinical Trials in 2025

VA-Sponsored Trials

Following the executive order, the VA launched clinical trials studying ibogaine for veterans with treatment-resistant PTSD and addiction. These trials are enrolling active participants in 2025 and represent the first federally funded ibogaine research in the United States. Results are expected in 2026–2027.

MAPS-Associated Research

The Multidisciplinary Association for Psychedelic Studies (MAPS), which successfully navigated MDMA through Phase 3 trials for PTSD treatment (before an FDA setback in 2024), has research teams involved in ibogaine protocol development. Their experience with psychedelic trial design is being applied to ibogaine research programs.

Canadian Clinical Programs

Canada’s more permissive research environment has allowed several Phase 1 and Phase 2 studies to proceed. Health Canada has approved compassionate access programs for ibogaine in cases of treatment-resistant opioid use disorder, and researchers at the University of British Columbia and other institutions are conducting formal trials.

European Research Programs

The Netherlands, Belgium, and Switzerland — countries with historically open approaches to psychedelic research — have active ibogaine research programs. We have not been able to verify a published Dutch outcome study of this kind, and we will not cite one until we can. The verifiable European-linked data remains the New Zealand 12-month follow-up (Noller et al., 2018, n=14).

The FDA Pathway: What Would Approval Look Like?

Ibogaine is currently a Schedule I controlled substance in the United States, which creates significant barriers to research and treatment — but not insurmountable ones. Here is what the path to potential FDA approval could look like:

1. Breakthrough Therapy Designation — If Phase 2 trial results are strong (which existing data suggests they will be), the FDA could grant Breakthrough Therapy status, accelerating the review process. MDMA and psilocybin have both received this designation.
2. Phase 3 Trials — Randomized controlled trials with larger patient populations. Estimated timeline: 2026–2029.
3. FDA Review — If Phase 3 data holds, estimated potential approval window: 2030–2032.
4. Rescheduling — Approval would require rescheduling from Schedule I, likely to Schedule II or III.

This timeline means patients who need treatment now cannot wait for FDA approval. Mexico remains the primary legal option for Americans seeking ibogaine treatment today.

The Noribogaine Research Track

Separate from ibogaine itself, researchers are studying noribogaine — ibogaine’s primary metabolite — as a potentially safer alternative that provides similar therapeutic benefits with a reduced cardiac risk profile. Noribogaine has a longer half-life than ibogaine and does not appear to prolong the QTc interval as significantly. Several companies have synthetic noribogaine programs in early development.

18-MC: The Next-Generation Derivative

Savant HWP has developed 18-methoxycoronaridine (18-MC), a synthetic ibogaine derivative designed to maintain anti-addictive properties while eliminating the hallucinogenic effects and cardiac risks. Phase 1 safety trials are complete. Phase 2 trials for opioid use disorder are underway. If successful, 18-MC could provide an FDA-approvable pathway for ibogaine-like treatment in the U.S.

What This Means for People Seeking Treatment Now

The research trajectory is overwhelmingly positive — but “overwhelmingly positive” doesn’t help someone in the grip of opioid addiction or PTSD right now. Here is the practical reality:

• Full ibogaine treatment remains available in Mexico and several other countries today, legally, under medical supervision
• The body of evidence supporting its use has never been stronger
• Costs have become more standardized as the industry matures ($5,000–$15,000 for full programs)
• Medical protocols have improved significantly following years of real-world clinical experience

Waiting for FDA approval means waiting potentially 7–10 more years. For people with severe opioid addiction or treatment-resistant PTSD, that wait has real costs — including, for many, their lives.